Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis

F. Blasi, T. Schaberg, S. Centanni, A. Del Vecchio, M. T. Rosignoli, P. Dionisio

Research output: Contribution to journalArticlepeer-review

Abstract

Rationale: Antimicrobial therapy of chronic bronchitis exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) is based on empiric antibiotic treatment. Objectives: To evaluate the efficacy of prulifloxacin versus levofloxacin therapy in severe COPD patients with exacerbations of chronic bronchitis. Methods: This study involved a multicenter, parallel, double-blind, randomized clinical trial. Patients aged 40 years or older, smokers, or ex-smokers (10 pack-years) with spirometrically confirmed severe COPD (FEV1≤50% predicted and FEV1/FVC ratio

Original languageEnglish
Pages (from-to)609-616
Number of pages8
JournalPulmonary Pharmacology and Therapeutics
Volume26
Issue number5
DOIs
Publication statusPublished - Oct 2013

Keywords

  • Antibacterial agents
  • Chronic obstructive pulmonary disease
  • Exacerbation
  • Levofloxacin
  • Prulifloxacin
  • Randomized controlled clinical trial

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)
  • Biochemistry, medical

Fingerprint

Dive into the research topics of 'Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis'. Together they form a unique fingerprint.

Cite this